Lessons for COVID-19 Immunity from Other Coronavirus Infections

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677

Clinical and immunological features of severe and moderate coronavirus disease 2019

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984

Antibody responses to SARS-CoV-2 in patients with COVID-19

Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876

A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong

Lee, N. L. S., Hui, D. S. C., Wu, A. K. L., Chan, P. K. S., Cameron, P. A., Joynt, G. M., Ahuja, A. T., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,638

Overview of Nonhuman Primate Models of SARS-CoV-2 Infection

Trichel, A. M. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-20-000119 · Cited by 28

Activation of TCA cycle restrains virus-metabolic hijacking and viral replication in mouse hepatitis virus-infected cells

Lee, S. R., ROH, J., Ryu, J., Shin, H., & Hong, E. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00740-z · Cited by 27

Identification of HLA-A*02:01-Restricted Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 That May Be Natural Targets of CD8 + T Cell Recognition In Vivo

Takagi, A., & Matsui, M. (2020) · Journal of Virology · doi:10.1128/jvi.01837-20 · Cited by 25

PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease

Vega, M. D., Olivera, D., Davanzo, G. G., Bertullo, M., Noya, V., de Souza, G. F., Muraro, S. P., de Castro, Í. M. S., Arévalo, A. P., Crispo, M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn6545 · Cited by 26

Variants of SARS-CoV-2: Influences on the Vaccines’ Effectiveness and Possible Strategies to Overcome Their Consequences

Rabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 26

Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?

Meyerholz, D. K., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144807 · Cited by 22

COVID-19 Vaccines: Current Conditions and Future Prospects

Zieneldien, T., Kim, J., Cao, J. A., & Cao, C. (2021) · Biology · doi:10.3390/biology10100960 · Cited by 24

SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases

Larionova, R., Byvaltsev, K., Kravtsova, O. A., Takha, E., Petrov, S. V., Kazarian, G. G., Рафкатовна, В. А., Shuralev, E. A., Mukminov, M. N., Renaudineau, Y., et al. (2022) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2022.100154 · Cited by 24

Immunoaffinity biosensors for the detection of SARS-CoV-1 using screened Fv-antibodies from an autodisplayed Fv-antibody library

Jung, J., Bong, J.-H., Sung, J. S., Park, J.-H., Kim, T., Kwon, S., Kang, M., Jose, J., & Pyun, J. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115439 · Cited by 24

Coronavirus Receptors as Immune Modulators

Devarakonda, C. K. V., Meredith, E. K., Ghosh, M., & Shapiro, L. H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001062 · Cited by 22

Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates

Karakuş, G. S., Taştan, C., Kançağı, D. D., Yurtsever, B., Tümentemur, G., Demir, S., Turan, R. D., Abanuz, S., Çakırsoy, D., Seyis, U., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83930-6 · Cited by 22

The role of T‐cell immunity in COVID‐19 severity amongst people living with type II diabetes

Tong, Z. W. M., Grant, E. J., Gras, S., Wu, M., Smith, C., Barrett, H. L., Gallo, L. A., & Short, K. R. (2021) · FEBS Journal · doi:10.1111/febs.16105 · Cited by 23

Isolation of Antibodies Against the Spike Protein of SARS-CoV from Pig Serum for Competitive Immunoassay

Jung, J., Bong, J.-H., Kim, T. H., Sung, J. S., Lee, C., Kang, M., Kim, H. O., Shin, H., & Pyun, J. (2021) · BioChip Journal · doi:10.1007/s13206-021-00033-0 · Cited by 22

Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids

Li, P., Wang, Y., Lamers, M. M., Lavrijsen, M., Iriondo, C., de Vries, A. C., Rottier, R. J., Peppelenbosch, M. P., Haagmans, B. L., & Pan, Q. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104132 · Cited by 21

A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice

Chaparian, R. R., Harding, A. T., Hamele, C. E., Riebe, K. J., Karlsson, A., Sempowski, G. D., Heaton, N. S., & Heaton, B. E. (2022) · Journal of Virology · doi:10.1128/jvi.00689-22 · Cited by 26

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Mahalingam, S., Peter, J., Xu, Z., Bordoloi, D., Ho, M., Kalyanaraman, V. S., Srinivasan, A., & Muthumani, K. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06836 · Cited by 20

SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma

Deere, J. D., Carroll, T. D., Dutra, J., Fritts, L., Sammak, R. L., Yee, J. L., Olstad, K. J., Reader, J. R., Kistler, A. L., Kamm, J., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01397-21 · Cited by 19

Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8+ T Cell Response in HLA-A Transgenic Mice

Shen, A.-R., Jin, X.-X., Tang, T.-T., Ding, Y., Liu, X.-T., Zhong, X., Wu, Y.-D., Han, X.-L., Zhao, G.-Y., Shen, C.-L., et al. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s367494 · Cited by 19

Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study

Vázquez‐Alejo, E., Tarancón‐Díez, L., Espinar-Buitrago, M. D. L. S., Genebat, M., Calderón, A., Pérez-Cabeza, G., Magro-López, E., Leal, M., & Muñoz‐Fernández, M. Á. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103539 · Cited by 21

A Review of the Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: Implications and Solutions

Sundaram, S., Olson, S., Sharma, P., & Rajendra, S. (2021) · Pathogens · doi:10.3390/pathogens10111508 · Cited by 21

A New Hypothesis on Anxiety, Sleep Insufficiency, and Viral Infections; Reciprocal Links to Consider in Today's “World vs. COVID-19” Endeavors

Nami, M., Mehrabi, S., Kamali, A., Kazemiha, M., Carvalho, J., Derman, S., Lakey‐Beitia, J., Vasquez, V., & Rao, K. S. J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.585893 · Cited by 20

Early approval of COVID-19 vaccines: Pros and cons

Rahman, M. A., & Islam, M. S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1944742 · Cited by 24

Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries

Hussain, A., Rafeeq, H., Asif, H. M., Shabbir, S., Bilal, M., Mulla, S. I., Franco, M., & Iqbal, H. M. N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108050 · Cited by 20

A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.

Mohamed, Y., El‐Maradny, Y. A., Saleh, A. K., Nayl, A. A., El‐Gendi, H., & El‐Fakharany, E. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113499 · Cited by 20

The Possible Role of Sex As an Important Factor in Development and Administration of Lipid Nanomedicine-Based COVID-19 Vaccine

Vulpis, E., Giulimondi, F., Digiacomo, L., Zingoni, A., Safavi‐Sohi, R., Sharifi, S., Caracciolo, G., & Mahmoudi, M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00291 · Cited by 21

Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort

Vo, H. T. M., Maestri, A., Auerswald, H., Sorn, S., Lay, S., Seng, H., Sann, S., Ya, N., Pean, P., Dussart, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817905 · Cited by 19

Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies

Reinig, S., & Shih, S. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100666 · Cited by 22

Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?

Gussarow, D., Bonifacius, A., Cossmann, A., Stankov, M. V., Mausberg, P., Tischer‐Zimmermann, S., Gödecke, N., Kalinke, U., Behrens, G. M. N., Blasczyk, R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.770381 · Cited by 18

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies

Zhang, F., Jenkins, J., de Carvalho, R. A., Nakandakari-Higa, S., Chen, T., Abernathy, M. E., Baharani, V. A., Nyakatura, E. K., Andrew, D. P., Lebedeva, I. V., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01389-9 · Cited by 21

Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP

Keshavarz, B., Wiencek, J. R., Workman, L. J., Straesser, M. D., Muehling, L. M., Canderan, G., Drago, F., Bonham, C. A., Sturek, J. M., Ramani, C., et al. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514203 · Cited by 16

Nanoparticles for Coronavirus Control

Kianpour, M., Akbarian, M., & Uversky, V. N. (2022) · Nanomaterials · doi:10.3390/nano12091602 · Cited by 17

Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives

Mayor, A., Chesnay, A., Désoubeaux, G., Ternant, D., Heuzé‐Vourc'h, N., & Sécher, T. (2021) · Vaccines · doi:10.3390/vaccines9020151 · Cited by 16

Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia

Alshukairi, A. N., Zhao, J., Al-Mozaini, M., Wang, Y., Dada, A. M., Baharoon, S. A., Alfaraj, S., Ahmed, W., Enani, M. A., Elzein, F. E., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2705.204056 · Cited by 17

COVID-19 and First Responder Social Workers: An Unexpected Mental Health Storm

Davies, H., & Cheung, M. (2022) · Social Work · doi:10.1093/sw/swac007 · Cited by 20

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern

Lyski, Z. L., Brunton, A. E., Strnad, M., Sullivan, P. E., Siegel, S. A. R., Tafesse, F., Slifka, M. K., & Messer, W. B. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab585 · Cited by 16

A GABA-receptor agonist reduces pneumonitis severity, viral load, and death rate in SARS-CoV-2-infected mice

Tian, J., Dillion, B. J., Henley, J. E., Comai, L., & Kaufman, D. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007955 · Cited by 16

The Immune Responses against Coronavirus Infections: Friend or Foe?

Vafaeinezhad, A., Atashzar, M. R., & Baharlou, R. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000516038 · Cited by 15

Immune Responses against SARS-CoV-2—Questions and Experiences

Mangge, H., Kneihsl, M., Schnedl, W. J., Sendlhofer, G., Curcio, F., & Domenis, R. (2021) · Biomedicines · doi:10.3390/biomedicines9101342 · Cited by 16

Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19

Jeong, H., Lee, J. S., Ko, J., Hong, S., Oh, S. T., Choi, S., Peck, K. R., Yang, J. H., Chung, S. H., Kim, S., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00964-8 · Cited by 17

Practical guidance for clinical laboratories for SARS-CoV-2 serology testing

Charlton, C. L., Kanji, J. N., Tran, V., Kus, J. V., Gubbay, J. B., Osiowy, C., Robinson, J. L., Sekirov, I., DREBOT, M. A., Hatchette, T. F., et al. (2021) · Canada Communicable Disease Report · doi:10.14745/ccdr.v47i04a01 · Cited by 14

An Immunoinformatics Approach for SARS-CoV-2 in Latam Populations and Multi-Epitope Vaccine Candidate Directed towards the World’s Population

Orduz, A. F. C., Díaz, L. L., Acosta, A. F., Peñaloza, M. K., Méndez, Y. R., Clavijo-Buriticá, D. C., & Yosa, J. (2021) · Vaccines · doi:10.3390/vaccines9060581 · Cited by 16

Predictors of impaired antibody response after SARS‐CoV ‐2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study

Mori, Y., Uchida, N., Harada, T., Katayama, Y., Wake, A., Iwasaki, H., Eto, T., Morishige, S., Fujisaki, T., Ito, Y., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26769 · Cited by 13

The Key to Increase Immunogenicity of Next‐Generation COVID‐19 Vaccines Lies in the Inclusion of the SARS‐CoV‐2 Nucleocapsid Protein

Mendoza‐Ramírez, N. J., García‐Cordero, J., Shrivastava, G., & Cedillo‐Barrón, L. (2024) · Journal of Immunology Research · doi:10.1155/2024/9313267 · Cited by 15

Immunological map in COVID-19

Li, C.-H., Chiou, H.-Y. C., Lin, M., Kuo, C., Lin, Y., Lin, Y.-C., Hung, C., & Kuo, C. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.04.006 · Cited by 16

Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia

Khan, A. A., Alahmari, A., Almuzaini, Y. S., Alamri, F. A., Alsofayan, Y., Aburas, A., Al‐Muhsen, S., Kerkhove, M. D. V., Yezli, S., Ciottone, G. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.727989 · Cited by 14

Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective

Kumar, A., Prasoon, P., Shekhawat, P. S., Pareek, V., Faiq, M. A., Kumari, C., Narayan, R. K., Kulandhasamy, M., & Kant, K. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1840566 · Cited by 12

The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals

Barrios, Y., Franco, A., Sánchez‐Machín, I., Guedes, P. P., González‐Pérez, R., & Matheu, V. M. (2021) · Vaccines · doi:10.3390/vaccines9060575 · Cited by 13

Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model

Day, J., Park, S., Ranard, B. L., Singh, H., Chow, C. C., & Yoram Vodovotz, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754127 · Cited by 13

Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection

Fu, Y., Chen, F., Cui, L., Zhao, Y., Zhang, H., Fu, S., & Zhang, J. (2021) · Vaccines · doi:10.3390/vaccines9091028 · Cited by 13

Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis

Karakizlis, H., Nahrgang, C., Strecker, K. E., Chen, J., Aly, M. G., Slanina, H., Schüttler, C. G., Esso, I., Wolter, M., Todorova, D., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108961 · Cited by 11

Small-molecule screening identifies Syk kinase inhibition and rutaecarpine as modulators of macrophage training and SARS-CoV-2 infection

John, S. P., Singh, A., Sun, J., Pierre, M. J., Alsalih, L., Lipsey, C. C., Traore, Z., Balcom-Luker, S., Bradfield, C. J., Song, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111441 · Cited by 14

Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms

Bayat, M., Asemani, Y., & Najafi, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107679 · Cited by 15

Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update

Mba, I. E., Sharndama, H. C., Osondu-chuka, G. O., & Okeke, O. P. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1916071 · Cited by 13

T cell responses to SARS-CoV-2 in humans and animals

Mattoo, S.-U.-S., & Myoung, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1624-z · Cited by 13

Deciphering the quality of SARS‐CoV‐2 specific T‐cell response associated with disease severity, immune memory and heterologous response

Pérez‐Gómez, A., Gasca‐Capote, C., Vitallé, J., Ostos, F. J., Serna‐Gallego, A., Trujillo‐Rodríguez, M., Muñoz‐Muela, E., Giráldez‐Pérez, T., Praena‐Segovia, J., Navarro-Amuedo, M. D., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.802 · Cited by 12

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11

Dynamic ensembles of SARS-CoV-2 N-protein reveal head-to-head coiled-coil-driven oligomerization and phase separation

Hernandez, G., Martins, M. L., Fernandes, N. P., Veloso, T., Lopes, J., Gomes, T., & Cordeiro, T. N. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf502 · Cited by 12

Immunouniverse of SARS-CoV-2

Jiménez, D., & Arias, M. T. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2066251 · Cited by 12

Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection

Kobayashi, K., Tachibana, M., & Tsutsumi, Y. (2021) · Innate Immunity · doi:10.1177/17534259211043159 · Cited by 11

SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers?Preprint

Wallace, S. K., Hall, V. J., Charlett, A., Kirwan, P., Cole, M. J., Shrotri, M., Rokadiya, S., Oguti, B., Vusirikala, A., Zambon, M. C. F. A., et al. (2020) · medRxiv · doi:10.1101/2020.12.15.20247981 · Cited by 11

Towards a Safer Future: Enhancing Vaccine Development to Combat Animal Coronaviruses

Si, F., Yu, R., Dong, S., Chen, B., Li, C., & Song, S. (2024) · Vaccines · doi:10.3390/vaccines12030330 · Cited by 11

Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19

Adamczyk, B., Morawiec, N., Arendarczyk, M., Baran, M., Wierzbicki, K., Sowa, P., & Adamczyk-Sowa, M. H. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0051 · Cited by 11

Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan

Ishizaki, A., Bi, X., Nguyen, Q. T., Maeno, T., Hara, A., Nakamura, H., Kuramoto, S., Nishi, K., Ooe, H., & Ichimura, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273712 · Cited by 11

Searching for COVID-19 Antibodies in Czech Children—A Needle in the Haystack

Bloomfield, M., Pospíšilová, I., Cabelova, T., Šedivá, A., Ibrahimová, M., Bořecká, K., & Magner, M. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.597736 · Cited by 11

Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motifPreprint

Hauser, B. M., Sangesland, M., Lam, E. C., Denis, K. S., Feldman, J. E., Yousif, A. S., Caradonna, T. M., Kannegieter, T., Balazs, A. B., Lingwood, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.07.415216 · Cited by 11

Evaluation of risk factors associated with SARS-CoV-2 transmission

Luu, M. N., Alhady, S. T. M., Duc, N. T. M., Trường, L. V., Qarawi, A. T. A., Venkatesh, U., Tiwari, R., Rocha, I. C. N., Minh, L. H. N., Ravikulan, R., et al. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2125258 · Cited by 9

An easy pipeline for one-step purification of SARS-CoV-2 nucleocapsid protein from insect cell suspension culture

de Camargo, B. R., da Silva, L. A., de Oliveira, A. S., & Ribeiro, B. M. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114341 · Cited by 10

A runtime alterable epidemic model with genetic drift, waning immunity and vaccinations

Getz, W. M., Salter, R. M., Vissat, L. L., Koopman, J. S., & Simon, C. P. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0648 · Cited by 12

A real-world data validation of the value of early-stage SIR modelling to public health

Liu, T., Huang, J. V., He, Z., Zhang, Y., Yan, N., Zhang, C. J. P., & Ming, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-36386-9 · Cited by 10

IL-2 and IFN-γ are biomarkers of SARS-CoV-2 specific cellular response in whole blood stimulation assaysPreprint

Pérez‐Cabezas, B., Ribeiro, R. J. T., Costa, I., Esteves, S., Teixeira, A. R., Reis, T., Monteiro, R., Afonso, A., Pinheiro, V. C. A., Antunes, M. I., et al. (2021) · medRxiv · doi:10.1101/2021.01.04.20248897 · Cited by 11

Lymphopenia with Altered T Cell Subsets in Hospitalized COVID-19 Patients in Pune, India

Suryawanshi, P. V., Patil‐Takbhate, B., Athavale, P. V., Jali, P., MEMANE, N. S., MIRZA, S. B., Karandikar, M. S., Kakrani, A. L., Kanitkar, S. A., Gandham, N. R., et al. (2023) · Viral Immunology · doi:10.1089/vim.2022.0123 · Cited by 8

Humanized mice for investigating SARS‐CoV‐2 lung infection and associated human immune responses

Sun, R., Zhao, Z., Fu, C., Wang, Y., Guo, Z., Zhang, C., Liu, L., Zhang, C., Shu, C., He, J., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202249804 · Cited by 12

Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children

Li, N., Li, X., Wu, J., Zhang, S., Zhu, L., Chen, Q., Fan, Y., Wu, Z., Xie, S., Chen, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1042406 · Cited by 9

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants

Vega, M.-A. D. L., Polychronopoulou, E., Ara, X. I. I. I., Ding, Z., Chen, T., Liu, Q., Lan, J., Nepveu-Traversy, M.-É., Fausther‐Bovendo, H., Zaidan, M., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2169198 · Cited by 10

An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19

Monzavi, S. M., Naderi, M., Ahmadbeigi, N., Kajbafzadeh, A. M., & Muhammadnejad, S. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104398 · Cited by 8

COVID-19 vaccines and coronavirus 19 variants including alpha, delta, and omicron: present status and future directions

Eisenhut, M., & Shin, J. I. (2022) · Life Cycle · doi:10.54724/lc.2022.e4 · Cited by 9

Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic

Li, X., Zhang, Y., He, L., Si, J., Qiu, S., He, Y., Wei, J., Wang, Z., Xie, L., Li, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66369 · Cited by 8

SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors

Duan, L., Cui, X., Zhu, K.-L., Lin, Y., Wang, G., Cao, W., & Ma, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111284 · Cited by 8

Rapid and Visual Detection of SARS-CoV-2 RNA Based on Reverse Transcription-Recombinase Polymerase Amplification with Closed Vertical Flow Visualization Strip Assay

Song, Y., Huang, P., Yu, M., Li, Y., Jin, H., Qiu, J., Li, Y., Gao, Y., Zhang, H., & Wang, H. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02966-22 · Cited by 8

Type I interferon pathway genetic variants in severe COVID-19

Montenegro, A. F. L., Clementino, M., & Yaochite, J. N. U. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199339 · Cited by 8

Surviving Older Patients Show Preserved Cellular and Humoral Immunological Memory Several Months After SARS-CoV-2 Infection

García‐Torre, A., Bueno‐García, E., López‐Martínez, R., Rioseras, B., Moro‐García, M. A., Alonso, S., Lluna-González, A., Sousa-Fernández, A., Fernández-Gudin, M., Campos-Riopedre, L., et al. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab206 · Cited by 7

Role of the cellular immunity in the formation of the immune response in coronavirus infections

Ia, I., Omelchenko, N. D., Filippenko, A. V., Trufanova, A. A., & Носков, А. К. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-rot-2302 · Cited by 11

Optimizing Spatio-Temporal Allocation of the COVID-19 Vaccine Under Different Epidemiological Landscapes

Cao, W., Zhu, J., Wang, X., Tong, X., Tian, Y., Dai, H., & Ma, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.921855 · Cited by 8

Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study

Atti, A., Ferrari, M., Castillo‐Olivares, J., Monk, E. J. M., Gopal, R., Patel, M., Höschler, K., Cole, M. J., Semper, A. E., Hewson, J., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.09.019 · Cited by 8

A mechanistic model for airborne and direct human-to-human transmission of COVID-19: effect of mitigation strategies and immigration of infectious persons

Pal, S., & Ghosh, I. (2022) · The European Physical Journal Special Topics · doi:10.1140/epjs/s11734-022-00433-9 · Cited by 8

The COVID-19 Pandemic—A Potential Role for Antivirals in Mitigating Pandemics

Neumann, G., & Kawaoka, Y. (2023) · Viruses · doi:10.3390/v15020303 · Cited by 6

Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic Coronaviridae and SARS-CoV-2

Fink, S., Ruoff, F., Stahl, A., Becker, M., Kaiser, P., Traenkle, B., Junker, D., Weise, F., Ruétalo, N., Hörber, S., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00725 · Cited by 6

Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

Galván, V., & Quarleri, J. F. (2021) · GeroScience · doi:10.1007/s11357-021-00501-3 · Cited by 7

Respiratory infections due to human common cold coronaviruses, SARS-CoV, MERS-CoV, and SARS-CoV-2: epidemiology, pathogenesis, clinical features, diagnostics, therapeutics, and vaccine landscapes

Zumla, A. I., Hui, D. S. C., Peiris, M. J. S., & Perlman, S. M. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00049-4 · Cited by 7

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development

Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 8

Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity

Vignals, C., Dick, D. W., Thiébaut, R., Wittkop, L., Prague, M., & Heffernan, J. M. (2021) · COVID · doi:10.3390/covid1020041 · Cited by 6

In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2

Matsabisa, M. G., Alexandre, K. B., Ibeji, C. U., Tripathy, S., Erukainure, O. L., Malatji, K. B., Chauke, S. H., Okole, B., & Chabalala, H. P. (2022) · Scientific Reports · doi:10.1038/s41598-022-13599-y · Cited by 7

Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection

Lagousi, T., Routsias, J. G., Mavrouli, M. D., Papadatou, I., Geropeppa, M., & Spoulou, V. I. (2022) · Vaccines · doi:10.3390/vaccines10081210 · Cited by 6

Combination of Recombinant Proteins S1/N and RBD/N as Potential Vaccine Candidates

Mendoza‐Ramírez, N. J., García‐Cordero, J., Martínez-Frías, S. P., Roa-Velázquez, D., Lurı́a-Pérez, R., Bustos‐Arriaga, J., Hernández, J., Cabello-Gutiérrez, C., Zúñiga, J., Morales‐Ríos, E., et al. (2023) · Vaccines · doi:10.3390/vaccines11040864 · Cited by 6

Longitudinal Analysis of Memory T-Cell Responses in Survivors of Middle East Respiratory Syndrome

Shin, H., Kim, Y., Kang, J., Um, J., Park, J. S., Park, W. B., Ys, K., Choi, J., Rhee, J.-Y., Joh, J.-S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1019 · Cited by 7

Severe acute respiratory syndrome coronavirus 2 invasion in the central nervous system: a host-virus deadlock

Baral, P. K., Nuruzzaman, M., Uddin, M. S., Ferdous, M., Chowdhury, I. H., & Smrity, S. Z. (2021) · Acta Virologica · doi:10.4149/av_2021_201 · Cited by 6

Promising Immunotherapies against COVID‐19

Guo, H., Zhou, L., Ma, Z., Tian, Z., & Zhou, F. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100044 · Cited by 6

Spotlight on COVID‐19: from biology to therapy and prevention

Zacchigna, S., Marcello, A., & Banks, L. (2020) · FEBS Journal · doi:10.1111/febs.15530 · Cited by 6

The cholesterol metabolite 25-hydroxycholesterol suppresses porcine deltacoronavirus via lipophagy inhibition and mTORC1 modulation

Zhang, J.-L., Wang, X.-F., Li, J.-L., Duan, C., & Wang, J.-F. (2025) · Veterinary Research · doi:10.1186/s13567-025-01452-9 · Cited by 5

Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19

Sell, S. L., Prough, D. S., Weisz, H. A., Widen, S. G., & Hellmich, H. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257965 · Cited by 4

Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses

Kim, K., Hwang, I., Ku, K. B., Lee, S., Kim, S., & Kim, C. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2006.06006 · Cited by 37

COVID-19: a review from origin to immune responsesPreprint

Vafaeinezhad, A., Atashzar, M. R., & Baharlou, R. (2022) · doi:10.22541/au.164864737.73751616/v1

The Immune Responses against Coronavirus Infections: Friend or Foe?

Vafaeinezhad, A., Atashzar, M. R., & Baharlou, R. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000516038 · Cited by 15

Early Insights into Immune Responses during COVID-19

John, A. L. S., & Rathore, A. P. S. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000526 · Cited by 50

SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines

León-Rodríguez, S. G. D., Hernández-Rico, B., Olmo-Vázquez, G. D., Cruz-Dávalos, I., & Bonifaz, L. C. (2020) · Boletín Médico del Hospital Infantil de México · doi:10.24875/bmhim.200001911 · Cited by 8